Janssen Seeks to Expand Use of TREMFYA (guselkumab) in the Treatment of Adults With Active Psoriatic…
The Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of a Type II Variation Application to the European Medicines Agency (EMA) seeking first-in-class…
Read More...
Read More...
